TY - JOUR
T1 - Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder
T2 - A cross-disorder proteomics analysis
AU - Çakici, N.
AU - Bot, Mariska
AU - Lamers, F.
AU - Janssen, Thomas
AU - van der Spek, Peter J.
AU - de Haan, Lieuwe
AU - Bahn, Sabine
AU - Penninx, Brenda W.J.H.
AU - van Beveren, Nico J.M.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - We investigated whether there are similar serum alterations in schizophrenia and major depressive disorder (MDD). We investigated serum analytes in two epidemiological studies on schizophrenia (N = 121) and MDD (N = 1172) versus controls. Serum analytes (N = 109) were measured with a multi-analyte profiling platform and analysed using linear regression models, adjusted for site, age, gender, ethnicity, anti-inflammatory agents, smoking, cardiovascular disease and diabetes, and adjusted for multiple comparisons. An increase in leptin and insulin levels was observed for both schizophrenia patients (Cohen's d (d): 0.26 and 0.65, respectively) and MDD patients (d: 0.29 and 0.12, respectively) compared to their respective controls. Lower angiopoietin-2 levels were seen in both schizophrenia (d: -0.22) and MDD (d: -0.13). Four analytes differed in only schizophrenia patients (increased levels of C-peptide and prolactin, and decreased levels of CD5 antigen-like and sex hormone binding globulin) and one analyte differed in only MDD patients (increased angiotensinogen levels) compared to their respective controls. Restricting analyses to patients with a current episode of disease showed even more marked elevations of insulin and leptin. Our results suggest the presence of insulin and leptin resistance as cross-disorder mechanisms that could contribute to the higher somatic comorbidity and decreased life-span seen in both disorders.
AB - We investigated whether there are similar serum alterations in schizophrenia and major depressive disorder (MDD). We investigated serum analytes in two epidemiological studies on schizophrenia (N = 121) and MDD (N = 1172) versus controls. Serum analytes (N = 109) were measured with a multi-analyte profiling platform and analysed using linear regression models, adjusted for site, age, gender, ethnicity, anti-inflammatory agents, smoking, cardiovascular disease and diabetes, and adjusted for multiple comparisons. An increase in leptin and insulin levels was observed for both schizophrenia patients (Cohen's d (d): 0.26 and 0.65, respectively) and MDD patients (d: 0.29 and 0.12, respectively) compared to their respective controls. Lower angiopoietin-2 levels were seen in both schizophrenia (d: -0.22) and MDD (d: -0.13). Four analytes differed in only schizophrenia patients (increased levels of C-peptide and prolactin, and decreased levels of CD5 antigen-like and sex hormone binding globulin) and one analyte differed in only MDD patients (increased angiotensinogen levels) compared to their respective controls. Restricting analyses to patients with a current episode of disease showed even more marked elevations of insulin and leptin. Our results suggest the presence of insulin and leptin resistance as cross-disorder mechanisms that could contribute to the higher somatic comorbidity and decreased life-span seen in both disorders.
KW - Cross-disorder
KW - Depressive disorder
KW - Insulin resistance
KW - Leptin
KW - Proteomics
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85067497648&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067497648&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31230885
U2 - https://doi.org/10.1016/j.euroneuro.2019.05.010
DO - https://doi.org/10.1016/j.euroneuro.2019.05.010
M3 - Article
C2 - 31230885
SN - 0924-977X
VL - 29
SP - 835
EP - 846
JO - European neuropsychopharmacology
JF - European neuropsychopharmacology
IS - 7
ER -